Spots Global Cancer Trial Database for Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
Official Title: A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Study ID: NCT01453504
Conditions
Study Description
Brief Summary: The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1st Dept. of Medicine, Cologne University Hospital, Cologne, , Germany
Contact Details
Name: Peter Borchmann, Prof.
Affiliation: University of Cologne, German Hodgkin Study Group
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
